002566.SZ
益盛药业
SZSE · Healthcare · C 制造业 · CN
CNY 6.74
−0.74%Aug 24, 2026, 13:09 UTC
Yisheng Pharmaceutical announced its first-half 2026 results with revenue of 338 million yuan, up 3.25% year-on-year, and net profit attributable to shareholders of 26.83 million yuan, up 42.99%.
Source:Jul 7, 2026, 09:12 UTC
Yisheng Pharmaceutical initiated a product recall and launched a comprehensive self-inspection and rectification campaign across its production system.
Source:Jul 5, 2026, 08:33 UTC
Yisheng Pharmaceutical received a notice from Jilin Provincial Drug Administration on July 1, 2026, ordering the suspension of production and sales of Shengmai Injection and Bujin Tablets due to serious defects and safety hazards found during an inspection from June 26 to 28, 2026.